Die wichtigsten Manuskripte sind publiziert in:
Annals of Transplantation, Cancer Cell, Cell Death and Differentiation, Cancer Discovery, Clinical Cancer Research, Endoskopy, Journal of Molecular Medicine, Hepatology, Oncology.

  1. Hoffmann K, Ganten TM, Gotthardtp D, Radeleff B, Settmacher U, Kollmar O, Nadalin S, Karapanagiotou-Schenkel I, von Kalle C, Jäger D, Büchler MW, Schemmer P. Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial. BMC Cancer. 2015 May 11;15(1):392.

  2. Ganten MK, Schuessler M, Bruckner T, Ganten TM, Koschny R. Pancreatic Atrophy in Hepatocellular Carcinoma Patients Receiving Long-Term Treatment with Sorafenib. Oncology. 2015 Apr 2. PubMed PMID: 25871578.

  3. von Karstedt S, Conti A, Nobis M, Montinaro A, Hartwig T, Lemke J, Legler K, Annewanter F, Campbell AD, Taraborrelli L, Grosse-Wilde A, Coy JF, El-Bahrawy MA, Bergmann F, Koschny R, Werner J, Ganten TM, Schweiger T, Hoetzenecker K, Kenessey I, Hegedüs B, Bergmann M, Hauser C, Egberts JH, Becker T, Röcken C, Kalthoff H, Trauzold A, Anderson KI, Sansom OJ, Walczak H. Cancer Cell-Autonomous TRAIL-R Signaling Promotes KRAS-Driven Cancer Progression, Invasion, and Metastasis. Cancer Cell. 2015 Apr 13;27(4):561-73.

  4. Koschny R, Krupp W, Xu LX, Mueller WC, Bauer M, Sinn P, Keller M, Koschny T, Walczak H, Bruckner T, Ganten TM, Holland H. WHO grade related expression of TRAIL-receptors and apoptosis regulators in meningioma. Pathol Res Pract. 2015 Feb;211(2):109-16.

  5. Koschny R, Boehm C, Sprick MR, Haas TL, Holland H, Xu LX, Krupp W, Mueller WC, Bauer M, Koschny T, Keller M, Sinn P, Meixensberger J, Walczak H, Ganten TM. Bortezomib sensitizes primary meningioma cells to TRAIL-induced apoptosis by enhancing formation of the death-inducing signaling complex. J Neuropathol Exp Neurol. 2014 Nov;73(11):1034-46.

  6. Hoffmann K, Hinz U, Hillebrand N, Ganten TM, Gotthardt D, Longerich T, Schirmacher P, Schemmer P. The MELD score predicts the short-term and overall survival after liver transplantation in patients with primary sclerosing cholangitis or autoimmune liver diseases. Langenbecks Arch Surg. 2014 Dec;399(8):1001-9

  7. Horwitz E, Stein I, Andreozzi M, Nemeth J, Shoham A, Pappo O, Schweitzer N, Tornillo L, Kanarek N, Quagliata L, Zreik F, Porat RM, Finkelstein R, Reuter H,Koschny R, Ganten TM, Mogler C, Shibolet O, Hess J, Breuhahn K, Grunewald M, Schirmacher P, Vogel A, Terracciano L, Angel P, Ben-Neriah Y, Pikarsky E. Human and Mouse VEGFA-Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment. Cancer Discov. 2014 Jun;4(6):730-43.

  8. Sterneck M, Settmacher U, Ganten TM, Sarrazin C, Speidel N, Broering D, Heyne N, Paulus E, Mertens M, Fischer L. Improvement in Gastrointestinal and Health-related Quality of Life Outcomes After Conversion From Mycophenolate Mofetil to Enteric-coated Mycophenolate Sodium in Liver Transplant Recipients. Transplant Proc. 2014 Jan-Feb;46(1):234-40.

  9. Brost S, Zimmermann A, Koschny R, Sykora J, Stremmel W, Schirmacher P, Walczak H, Ganten TM. Hepatocyte expression of TRAIL pathway regulators correlates with histopathological and clinical parameters in chronic HCV infection. Pathol Res Pract. 2014 Feb;210(2):83-91.

  10. Klein CG, Cicinnati V, Schmidt H, Ganten TM, Scherer MN, Braun F, Zeuzem S, Wartenberg-Demand A, Niemann G, Schmeidl R, Beckebaum S. Compliance and tolerability of subcutaneous hepatitis B immunoglobulin self-administration in liver transplant patients: A prospective, observational, multicenter study. Ann Transplant. 2013 Dec 13;18:677-84

  11. Koschny R, Brost S, Hinz U, Sykora J, Batke EM, Singer S, Breuhahn K, Stremmel W, Walczak H, Schemmer P, Schirmacher P, Ganten TM. Cytosolic and nuclear caspase-8 have opposite impact on survival after liver resection for hepatocellular carcinoma. BMC Cancer. 2013 Nov 9;13:532.

  12. Pfeiffenberger J, Koschny R, Hoffmann K, Mehrabi A, Schmitz A, Radeleff B, Stremmel W, Schemmer P, Ganten TM. Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation. Langenbecks Arch Surg. 2013 Oct 4.

  13. Zahn A, Mueller F, Hinz U, Schemmer P, Stremmel W, Ganten TM. Mycophenolate mofetil combination therapy improves survival after liver transplantation. A single-center retrospective analysis. Ann Transplant. 2013 Oct 3;18:525-532.

  14. Bobbert M, Ganten TM. Liver allocation: urgency of need or prospect of success? Ethical considerations. Clin Transplant. 2013 Jul-Aug;27 Suppl 25:34-9.

  15. Albarmawi A, Czock D, Gauss A, Ehehalt R, Bermejo JL, Burhenne J, Ganten TM, Sauer P, Haefeli WE. CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and Model for End-Stage Liver Disease (MELD) scores. Br J Clin Pharmacol. 2013 Jun 17.

  16. Franz C, Hoffmann K, Hinz U, Singer R, Hund E, Gotthardt DN, Ganten TM, Kristen AV, Hegenbart U, Schönland S, Hinderhofer K, Büchler MW, Schemmer P. Modified body mass index and time interval between diagnosis and operation affect survival after liver transplantation for hereditary amyloidosis: a single-center analysis. Clin Transplant. 2013 Jul-Aug;27 Suppl 25:40-8.

  17. Habermehl D, Debus J, Ganten TM, Ganten MK, Bauer J, Brecht IC, Brons S, Haberer T, Haertig M, Jäkel O, Parodi K, Welzel T, Combs SE. Hypofractionated carbon ion therapy delivered with scanned ion beams for patients with hepatocellular carcinoma - feasibility and clinical response. Radiat Oncol. 2013 Mar 13;8:59.

  18. Schlitt HJ, Jonas S, Ganten TM, Grannas G, Moench C, Rauchfuss F, Obed A, Tisone G, Pinna AD, Gerunda GE, Beckebaum S. Effects of mycophenolate mofetil introduction in liver transplant patients: results from an observational, non-interventional, multicenter study (LOBSTER). Clin Transplant. 2013 May;27(3):368-78.

  19. Katharina Esser-Nobis, Ines Romero-Brey, Ganten TM, Jerome Gouttenoire, Christian Harak, Rahel Klein, Peter Schemmer, Marco Binder, Paul Schnitzler, Darius Moradpour, Ralf Bartenschlager, Stephen J. Polyak, Wolfgang Stremmel, Francois Penin, Christoph Eisenbach2, Volker Lohmann. Analysis of hepatitis C virus resistance to Silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B. Hepatology 2013 Mar;57(3):953-63.

  20. Dai X, Schlemmer HP, Schmidt B, Höh K, Xu K, Ganten TM, Ganten MK. Quantitative therapy response assessment by volumetric iodine-uptake measurement: Initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib. Eur J Radiol. 2013 Feb;82(2):327-34

  21. Koschny R, Gotthardt D, Koehler C, Jaeger D, Wolfgang Stremmel, Ganten TM. Diarrhea Is a Positive Outcome Predictor for Sorafenib Treatment of Advanced Hepatocellular Carcinoma, Oncology  2013;84(1):6-13

  22. 22. Anadol E, Beckebaum S, Radecke K, Paul A, Zoufaly A, Bickel M, Hitzenbichler F, Ganten TM, Kittner J, Stoll M, Berg C, Manekeller S, Kalff JC, Sauerbruch T, Rockstroh JK, Spengler U. Orthotopic liver transplantation in human-immunodeficiency-virus-positive patients in Germany. AIDS Res Treat. 2012:197501

  23. Radeleff BA, Stampfl U, Sommer CM, Bellemann N, Hoffmann K, Ganten TM, Ehehalt R, Kauczor HU. [Transarterial ablation of hepatocellular carcinoma. Status and developments]. Radiologe. 2012 Jan;52(1):44-55.

  24. Sommer CM, Gockner TL, Stampfl U, Bellemann N, Sauer P, Ganten TM, Weitz J, Kauczor HU, Radeleff BA. Technical and clinical outcome of transjugular intrahepatic portosystemic stent shunt: Bare metal stents (BMS) versus viatorr stent-grafts (VSG). Eur J Radiol. 2011 Jul 22.

  25. Hoffmann K, Hinz U, Hillebrand N, Radeleff BA, Ganten TM, Schirmacher P, Schmidt J, Büchler MW, Schemmer P. Risk factors of survival after liver transplantation for HCC: a multivariate single-center analysis. Clin Transplant. 2011  Sep-Oct;25(5):E541-51.

  26. Zahn A, Schott N, Hinz U, Stremmel W, Schmidt J, Ganten TM, Gotthardt D, Meuer S, Zeier M, Giese T, Sommerer C. Immunomonitoring of nuclear factor of activated T cells-regulated gene expression: The first clinical trial in liver allograft recipients. Liver Transpl. 2011 Apr;17(4):466-73.

  27. Combs SE, Habermehl D, Ganten TM, Schmidt J, Edler L, Burkholder I, Jäkel O, Haberer T, Debus J. Phase i study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: the PROMETHEUS-01 trial. BMC Cancer. 2011 Feb 12;11:67.

  28. López-Benítez R, Wielpütz MO, Bryant MG, Ganten TM, Richter GM, Flach N, Hallscheidt PJ. Percutaneous Treatment of Biliary Cast Syndrome After Orthotopic Liver Transplantation: Comparison of Mechanical Versus Hydraulic Rheolytic Cast Extraction. Cardiovasc Intervent Radiol. 2010 Nov 12

  29. S Brost, R Koschny, J Sykora, W Stremmel, F Lasitschka, H Walczak, Ganten TM. Differential expression of the TRAIL/TRAIL-receptor system in patients with inflammatory bowel disease, Pathol Research and Pract 2010 Jan 15;206(1):43-50.

  30. Brost S, Wenzel JJ, Ganten TM, Filser M, Flechtenmacher C, Boehm S, Astani A, Jilg W, Zeier M, Schnitzler P. Sporadic cases of acute autochthonous hepatitis E virus infection in Southwest Germany. J Clin Virol. 2010 Jan;47(1):89-92.

  31. Koschny R, Holland H, Sykora J, Erdal H, Krupp W, Bauer M, Bockmuehl U, Ahnert P, Meixensberger J, Stremmel W, Walczak H, Ganten TM. Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis. J Neurooncol. 2010 Apr;97(2):171-85.

  32. Ganten TM, Sykora J, Koschny R, Batke E, Aulmann S, Mansmann U, Stremmel W, Sinn HP, Walczak H. Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer. J Mol Med. 2009 Oct;87(10):995-1007.

  33. Weigand K, Ganten TM, Andrulis M, Stremmel W, Sauer P, Schaible A. Chronic anemia masking a primary large B-cell lymphoma of the small intestine, finally diagnosed by double-balloon enteroscopy. Endoscopy. 2008 Sep;40 Suppl 2:E149.

  34. Kleber S, Sancho-Martinez I, Wiestler B, Beisel A, Gieffers C, Hill O, Thiemann M, Mueller W, Sykora J, Kuhn A, Schreglmann N, Letellier E, Zuliani C, Klussmann S, Teodorczyk M, Gröne HJ, Ganten TM, Sültmann H, Tüttenberg J, von Deimling A, Regnier-Vigouroux A, Herold-Mende C, Martin-Villalba A. Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell. 2008 Mar;13(3):235-48.

  35. Holland H, Koschny R, Krupp W, Meixensberger J, Bauer M, Schober R, Kirsten H, Ganten TM, Ahnert P. Cytogenetic and molecular biological characterization of an adult medulloblastoma. Cancer Genet Cytogenet. 2007 Oct 15;178(2):104-13.

  36. Gassler N, Roth W, Funke B, Schneider A, Herzog F, Tischendorf JJ, Grund K, Penzel R, Bravo IG, Mariadason J, Ehemann V, Sykora J, Haas TL, Walczak H, Ganten TM, Zentgraf H, Erb P, Alonso A, Autschbach F, Schirmacher P, Knüchel R, Kopitz J. Regulation of enterocyte apoptosis by acyl-CoA synthetase 5 splicing. Gastroenterology. 2007 Aug;133(2):587-98.

  37. Koschny R, Holland H, Sykora J, Haas TL, Sprick MR, Ganten TM, Krupp W, Bauer M, Ahnert P, Meixensberger J, Walczak H. Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin Cancer Res. 2007 Jun 1;13(11):3403-12.

  38. Ganten TM, Edmundo Aravena, Jaromir Sykora, Ronald Koschny, Jutta Mohr, Jochen Rudi, Wolfgang Stremmel, Henning Walczak. Helicobacter pylori-induced apoptosis in T cells is mediated by mitochondrial apoptosis and serves as a model of immune evasion. Eur J Clin Invest. 2007 Feb;37(2):117-25.

  39. Koschny R*, Ganten TM*, Sykora J, Haas TL, Sprick RM, Kolb A, Walcak H. TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology 2007 Mar;45(3):649-58.

  40. Koschny R, Holland H, Sykora J, Haas TL, Sprick MR, Ganten TM, Krupp W, Bauer M, Ahnert P, Meixensberger J, Walczak H. Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin Cancer Res. 2007 Jun 1;13(11):3403-12.

  41. Ganten TM*, Koschny R*, Sykora J, Schulze-Bergkamen H, Büchler P, Haas TL, Schader MB, Untergasser A, Stremmel W, Walczak H. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clinical Cancer Research (2006), Clin Cancer Res 12(8): 2640-6

  42. M Kornacker, MR Verneris, B Kornacker, Ganten TM, C Scheffold, RS Negrin. The apoptotic and proliferative fate of cytokine-induced killer cells after redirection to tumor cells with bispecific Ab Cytotherapy (2006) 8:13-23

  43. Ganten TM, Ronald Koschny, Tobias L. Haas, Jaromir Sykora, Min Li Weber, Kerstin Herzer, Peter Krammer and Henning Walczak Proteasome inhibition sensitises hepatocellular carcinoma cells but not primary human hepatocytes for TRAIL-induced apoptosis. Hepatology. (2005) 42: 588-597.

  44. Editorial: Anan A, Gores GJ. A new TRAIL to therapy of hepatocellular carcinoma: blocking the proteasome. Hepatology (2005) 42:527-529.

  45. Herzer K, Ganten TM, Schulze-Bergkamen H, Grosse-Wilde A, Koschny R, Krammer PH, Walczak H. Transforming growth factor beta can mediate apoptosis via the expression of TRAIL in human hepatoma cells. Hepatology (2005) 42:183-192.

  46. Ganten TM*, Haas TL*, Stahl H, Sprick MR, Weigand MA, Grosse-Wilde A, Stremmel W, Krammer PH, Walczak H. Enhanced DISC formation is responsible for sensitisation to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death and Differentiation (2004), Jul;11 Suppl 1:S86-96.

  47. Jendro MC, Ganten TM, Matteson EL, Weyand CM, Goronzy JJ. Emergence of oligoclonal T cell populations following therapeutic T cell depletion in rheumatoid arthritis. Arthritis Rheum. (1995) Sep;38(9):1242-51.

* gleichberechtigte Autoren

Bücher/Reviews

  1. Ganten MK, Ganten TM, Schlemmer HP. Radiological Monitoring of the Treatment of Solid Tumors in Practice. Rofo. 2014 2014 May;186(5):466-73

  2. Dannecker G, Streng A, Ganten TM. Die Allokation postmortal gespendeter Lebern in Theorie und klinischer Praxis aus rechtswissenschaftlicher Perspektive, in: Marsilius-Kolleg, 2013, S. 29 ff

  3. Workshopbericht 28/29. September 2012. Der Hochrisikopatient-Möglichkeiten und Grenzen der Transplantation. Thieme Blickpunkt Medizin. Juni 2013; 1-8

  4. Dannecker G, Streng AF, Ganten TM. Zur Reformbedürftigkeit des gegenwärtigen Allokationsmodus für postmortal gespendete Lebern –Vom „Sickest First“ -Prinzip zum „Most Lives Saved“ –Ansatz. Kölner Schriften zum Medizinrecht 2013;11:147-160

  5. Ganten TM, Schlitt HJ, Witzke O, Schmidt H. Management einer Everolimus-basierten Therapie nach Lebertransplantation. Thieme Praxis Report 2013;5:1-12

  6. Bobbert M, Dannecker G, Streng A, Ganten TM, Gleichheit und Ungleichheit in der Leberallokation: aktuelle Fragen klinischer Praxis und ihre Reflexion aus medizinischer, ethischer und rechtlicher Sicht, in: Marsilius-Kolleg, 2012, 31-60.

  7. Ganten TM, Dollinger M., Vogel A. Fortschritte in der Behandlung des hepatozellulären Karzinoms. Thieme-Refresher Innere Medizin 2012: R1-16

  8. Jan Pfeiffenberger, Jens Werner, Maria K. Ganten, Dirk Jäger, Ganten TM. Treating pancreatic cancer: challenges and perspectives. European Gastroenterology Review 2012

  9. Mehrabi A, Esmaeilzadeh M, Fonouni H, Hafezi M, Rahbari NN, Golriz M, Majlesara A, Rad MT, Sadeghi M, Schmidt J, Ganten TM. The role of HBIg as hepatitis B reinfection prophylaxis following liver transplantation. Langenbecks Arch Surg. 2012 Jun;397(5):697-710

  10. Radeleff BA, Stampfl U, Sommer CM, Bellemann N, Hoffmann K, Ganten TM, Ehehalt R, Kauczor HU. [Transarterial ablation of hepatocellular carcinoma. Status and developments]. Radiologe. 2012 Jan;52(1):44-55.

  11. Schönland S, Blank N, Kristen AV, Beimler J, Ganten TM, Hegenbart U. [Systemic amyloidoses]. Internist. 2012 Jan;53(1):51-64.

  12. Koschny R, Schmidt J, Ganten TM. Beyond Milan criteria--chances and risks of expanding transplantation criteria for HCC patients with liver cirrhosis. Clin Transplant. 2009 Dec;23 Suppl 21:49-60

  13. Koschny R, Grüllich C, Ganten TM. Standards und neue Aspekte der Diagnostik und Therapie des hepatozellulären Karzinoms. Onkopipeline 2008;3:109–19

  14. Ganten MK, Weber MA, Ganten TM. Cellular mechanisms of tumor response : Clinical demands. Radiologe. 2008 Sep;48(9):820-31. German.

  15. Buchmann I, Ganten TM, Haberkorn U. [18F]-FDG-PET in the diagnostics of gastrointestinal tumors Z Gastroenterol. 2008 Apr;46(4):367-75. Review.

  16. Koschny R, Walczak H, Ganten TM. The promise of TRAIL-potential and risks of a novel anticancer therapy. J Mol Med. 2007 Apr 17

  17. Walczak H, Koschny R, Willen D, Schader MB, Sykora J, Ganten TM, Haas TL. The TRAIL receptor-ligand system: biochemistry of apoptosis induction, therapeutic potential for cancer treatment and physiological function, Fulda S, Debatin KM (Editors) John Wiley & Sons 2006

  18. Hrsg. Ganten TM, Geiss HK, Stremmel W. Infektionen in der Gastroenterologie in Theorie und Praxis, UNI-MED Verlag Bremen 2004